COVID-19 Among Patients with Hematological Malignancies: Experience from a Tertiary Center Showing Lower Than Expected Mortality and Establishing the Safety of in-Hospital Patient Care during the Pandemic

Previous studies and meta-analyses addressing COVID-19 in patients with hematological malignancies (HM) have reported dramatically high mortality rates of up to 34% [Vigenthira 2020, Garcia-Suarez 2020, Sharafeldin 2021]. These studies, however, were strongly biased towards hospitalized patients, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Aumann, Shlomzion, Tsubary, Uria, Israel, Sarah, Ben Yehuda, Dina, Lavie, David, Goldschmidt, Neta, Vainstein, Vladimir, Libster, Diana, Saban, Revital, Shaulov, Adir, Avni, Batia, Nachmias, Boaz, Grisariu, Sigal, Paltiel, Ora, Gatt, Moshe, Zimran, Eran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
905.Outcomes Research-Lymphoid Malignancies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701601/
http://dx.doi.org/10.1182/blood-2021-148512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701601/
http://dx.doi.org/10.1182/blood-2021-148512

Ejemplares similares